In the secondary efficacy outcomes, there were no statistically significant differences in the COMP, COX-2, HS-CRP and ESR levels, and the neutrophil and lymphocyte ratio in the PFE group compared with the placebo group at the end of the intervention (Table 3). This evidence concerns the gene ESR1 and primary failure of tooth eruption.